ADME/Tox, IVIVE, virtual perturbation evidence, toxicokinetics, first-in-human dose, and organ-level safety - all connected, auditable, and ready for IND.
Recommended order: characterize the candidate, translate properties into expected exposure,
confirm disease-relevant cellular perturbation hypotheses where useful, confirm animal toxicokinetics, build the safety package, and then establish the clinical-entry dose rationale.
Steps marked A, B, or C are optional branches for the relevant program.